Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazarotene betamethasone cream versus halometasone cream for inflammatory lichenified or keratotic dermatoses
ChiCTR2500102080Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in atopic dermatitis (AD), neurodermatitis and primary cutaneous amyloidosis (PCA) comparing Tazarotene betamethasone cream group with Halometasone cream group (2 arms). Primary endpoint: Target lesion IGA 0/1 achievement. Planned start May 2025; status: not yet recruiting.
02
Drugs
betamethasone dipropionate + tazarotenehalometasone
03
Conditions
atopic dermatitis (AD)neurodermatitisprimary cutaneous amyloidosis (PCA)
Beyond the preview
Go deeper on ChiCTR2500102080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102080.